1. Pink Sheet

FTC Slams Surescripts' E-Prescribing Networks, Says 'Web Of Loyalty Contracts' Blocks Competition

 
• By Brenda Sandburg

Surescripts maintained a monopoly on electronic prescription routing and eligibility markets through exclusive contracts with pharmacies and PBMs, complaint alleges.

Pills and prescription on a smartphone isolated on green background. 3d illustration

The US Federal Trade Commission alleges that Surescripts LLC implemented a "web of exclusive contracts" with pharmacies and pharmacy benefit managers to eliminate competition in two electronic prescription markets.

In an April 17 complaint, FTC claims the company monopolized the market for routing electronic prescriptions, which uses technology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.